spermidine
Commercial- Indications
- Aging, Cardiovascular health
Company intelligence / Profile preview
Chrysea Labs has developed Sprevive®, the first pure spermidine supplement produced by precision fermentation with GRAS status in the US. Clinical trials have demonstrated safety at full dosing in humans, with minimal effects on circulating polyamines. The company is focused on science-backed, sustainable solutions to promote healthy lifespan through autophagy modulation.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Chrysea Labs.